Pulse Explorer nav.journalClub Débats Tendances Chercheurs Revues

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Accueil Explorer nav.journalClub Tendances

⌘+K

February 28, 2024Open Access

View Full Paper

Cost-effectiveness of nonavalent HPV vaccination in the Netherlands

CPCody PalmerMerck & Co., Inc., Rahway, NJ, USA (United States)FDF Christiaan K DolkMSD (Netherlands)USUgne SabaleMSD (Lithuania)

Key Points

Key points are not available for this paper at this time.

Abstract

Background A bivalent human papillomavirus vaccine (2vHPV) is currently used in the Netherlands; a nonavalent vaccine (9vHPV) is also licensed.

Demander à l'IA

Like

Bookmark

Share

View Full Paper

Demander à l'IA

Like

Bookmark

Share

View Full Paper

Cost-effectiveness of nonavalent HPV vaccination in the Netherlands | Synapse

Cite This Study

Palmer et al. (Wed,) studied this question.

synapsesocial.com/papers/68e77206b6db6435876e6db0 https://doi.org/https://doi.org/10.1080/14760584.2024.2322543

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cost‐effectiveness of HPV‐based cervical screening based on first year results in the Netherlands: a modelling study2020 · 63 citations
2Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands2007 · 48 citations
3United Nations Statistics Division2006 · 1,218 citations
4Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer2003 · 6,308 citations
5Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands2020 · 29 citations